Lannett Wins Approvals for Generic Adoxa Tablets
August 5, 2008
Lannett Company, a manufacturer of generic pharmaceutical products, has received approvals from the FDA of its abbreviated new drug applications for doxycycline tablets, 75mg and 150mg, the generic equivalent of Adoxa marketed by Par Pharmaceutical.
Doxycycline is indicated for the treatment of bacterial infections, such as urinary tract infections, acne, gonorrhea, chlamydia, periodontitis and others.
Arthur Bedrosian, president and CEO of Lannett, said: “The approvals of doxycycline tablets, 75mg and 150mg, round out our doxycycline portfolio, supplementing our 50mg and 100mg dosages. We will commence marketing our doxycycline tablets, 75mg and 150mg, immediately.”